Pyxis Oncology, Inc.
PYXS
$1.04
-$0.005-0.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -35.57M | -21.20M | -17.30M | -3.26M | -15.60M |
| Total Depreciation and Amortization | 550.00K | 731.00K | 585.00K | 1.12M | 690.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.30M | 1.51M | 1.41M | 3.20M | 1.96M |
| Change in Net Operating Assets | -6.56M | 4.30M | 12.30M | -21.77M | -2.31M |
| Cash from Operations | -19.29M | -14.67M | -3.01M | -20.71M | -15.25M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | -237.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 1.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.66M | -8.00K | 4.00K | -18.26M | 10.23M |
| Cash from Investing | 26.66M | -8.00K | 4.00K | -18.50M | 10.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.00K | 9.36M | 153.00K | 50.01M | 27.00K |
| Repurchase of Common Stock | 0.00 | -1.00K | -43.00K | -196.00K | -52.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -7.70M | 0.00 | 7.70M | -- |
| Cash from Financing | 50.00K | 1.66M | 110.00K | 57.51M | -25.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.42M | -13.02M | -2.89M | 18.30M | -5.05M |